Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia

15 Jul 2025

Abstract excerpt

The complexity of neurodegenerative disorders necessitates an integrative approach that incorporates morphological, functional, and molecular biomarkers. The advent of highly sensitive single-molecule array (Simoa®) assays has significantly enhanced the accuracy of blood-based biomarker quantification, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyotrophic Lateral Sclerosis Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40682931
DOI: 10.1016/j.jns.2025.123617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementiaPMID 40682931Read ↗

Plasma Biomarkers in the Distinction of Alzheimer’s Disease and Frontotemporal DementiaSemantic proximity Read ↗

Clinicopathological and prognostic correlations of plasma biomarkers in neurodegenerative diseasesSemantic proximity Read ↗

Plasma GFAP, NfL, and p-tau181 levels as early biomarkers of dementia in Chinese adults: Shenzhen community cohort studySemantic proximity Read ↗

Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers.Semantic proximity Read ↗

Differences in Blood and Cerebrospinal Fluid Between Parkinson’s Disease and Related DiseasesSemantic proximity Read ↗

Performance of Plasma Amyloid β, Total Tau and Neurofilament Light Chain Levels for Alzheimer’s Disease IdentificationSemantic proximity Read ↗

Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Semantic proximity Read ↗

Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and PrognosticsSemantic proximity Read ↗

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s diseaseSemantic proximity Read ↗

Plasma biomarker profiles in autosomal dominant Alzheimer’s diseaseSemantic proximity Read ↗

Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s diseaseSemantic proximity Read ↗

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism SyndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.